Literature DB >> 3856834

Differential pattern of DNA-aneuploidy in human malignancies.

T Büchner, W Hiddemann, B Wörmann, B Kleinemeier, J Schumann, W Göhde, J Ritter, K M Müller, D B von Bassewitz, A Roessner.   

Abstract

The differential pattern of DNA-aneuploidy, detected by flow cytometry (FCM) regarding its frequency, grade and multiclonality, was investigated and correlated to tumor type, malignancy grade, tumor stage and prognosis in a multi-institutional study at the University of Münster. High resolution measurements using admixed normal blood reference cells were undertaken in 2413 cases of 13 different malignant diseases and in 776 benign lesions or samples. The incidence of DNA-aneuploidy was highest in melanomas, carcinomas, testicular tumors, sarcomas (75%-95%) and myelomas (65%). Acute leukemias showed an intermediate DNA-aneuploidy rate of 40% with special subgroups represented by common ALL (44%), p less than 0.05) and myelomonocytic/monocytic AML (47%, p less than 0.01). The lowest DNA-aneuploidy-rate was found in basal cell skin carcinomas (19%) and congenital melanocytic nevi (9%). No case of DNA-aneuploidy was observed in the 776 benign lesions or samples.--DNA-indices giving the grade of DNA-aneuploidy with 1.0 for normal diploid G1/0 cells were found distributed predominantly between 1.0 and 2.0 in the solid tumors, except testicular tumors, clustering around a triploid maximum at 1.5. DNA-indices of myelomas and acute leukemias generally ranged below 1.25 with lower DNA-aneuploidy grades in AML than in ALL (p less than 0.01).--In melanomas the aneuploidy rate was higher (86%) in metastases than in the primary tumors (54%, p = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856834     DOI: 10.1016/s0344-0338(85)80140-0

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

1.  Co-existence of two aneuploid stemlines in benign adenomas.

Authors:  H Feichtinger; M Tötsch; K W Schmid; A R Weger; G Mikuz
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  DNA content and MHC class II antigen expression in malignant melanoma: clinical course.

Authors:  J Zaloudik; M Moore; A K Ghosh; Z Mechl; A Rejthar
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

3.  Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma.

Authors:  S M Kheir; S D Bines; J H Vonroenn; S J Soong; M M Urist; J S Coon
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

Review 4.  Management of the regional lymph nodes in patients with cutaneous malignant melanoma.

Authors:  A J Cochran; D R Wen; D L Morton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Co-existence of two aneuploid stemlines in benign adenomas. A report of three cases with stemline heterogeneity.

Authors:  H Joensuu; P J Klemi; K A Alanen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

6.  Epithelioid cell melanomas have greater DNA ploidy abnormalities than spindle cell melanomas: cytological evidence for a higher malignant potential of the former.

Authors:  H I Chi; Y Uyeda; Y Umebayashi; F Otsuka
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

7.  Heterogeneity in ploidy and S-phase fraction in colorectal adenocarcinomas.

Authors:  G Lindmark; B Glimelius; L Påhlman; P Enblad
Journal:  Int J Colorectal Dis       Date:  1991-05       Impact factor: 2.571

8.  Prognostic significance in malignant melanoma of nuclear DNA content measured by a microfluorimetric method.

Authors:  Y Umebayashi; F Otsuka
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  DNA aneuploidy in adenomas of endocrine organs.

Authors:  H Joensuu; P J Klemi
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

10.  Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; V M Wasenius; S Asko-Seljavaara; K Franssila; L Kangas
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.